Sipuleucel-T

Drug Profile

Sipuleucel-T

Alternative Names: APC-8015; APC8015F; Autologous PAP-loaded dendritic cell vaccine - Dendreon; Prostate cancer vaccine (APC-8015) - Dendreon; Provenge

Latest Information Update: 23 Jun 2017

Price : $50

At a glance

  • Originator Dendreon Corporation
  • Class Cancer vaccines; Dendritic cell vaccines; T lymphocyte cell therapies; Tissue extracts
  • Mechanism of Action CD8 positive T lymphocyte stimulants; Immunostimulants; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Prostate cancer

Most Recent Events

  • 03 Jun 2017 Pharmacodynamics data from the phase II STAND, STRIDE and STAMP trials in Prostate cancer presented at the annual meeting of American Society of Clinical Oncology (ASCO-2017)
  • 01 Jun 2017 Dendreon terminates a phase II trial in Prostate cancer (Metastatic disease) in USA (NCT01338012) prior to June 2017
  • 13 May 2017 Sub-group efficacy analysis data from a phase IV trial in Prostate cancer released by Dendreon
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top